Reply to K.R. Hoffman

Affiliations

Comment

Jorge E Cortes et al. J Clin Oncol. 2017.

. 2017 Feb 10;35(5):567-568.

doi: 10.1200/JCO.2016.70.2944. Epub 2016 Nov 14.

¹ Jorge E. Cortes, MD Anderson Cancer Center, Houston, TX; and Andreas Hochhaus, Universitätsklinikum Jena, Jena, Germany.

No abstract available

Comment on

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.
Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, Shah NP, Chuah C, Casanova L, Bradley-Garelik B, Manos G, Hochhaus A. Cortes JE, et al. J Clin Oncol. 2016 Jul 10;34(20):2333-40. doi: 10.1200/JCO.2015.64.8899. Epub 2016 May 23. J Clin Oncol. 2016. PMID: 27217448 Free PMC article. Clinical Trial.
How Does One Decide Which Tyrosine Kinase Inhibitor To Use for the Initial Treatment of Chronic-Phase Chronic Myeloid Leukemia?
Hoffman KR. Hoffman KR. J Clin Oncol. 2017 Feb 10;35(5):567. doi: 10.1200/JCO.2016.69.5940. Epub 2016 Nov 14. J Clin Oncol. 2017. PMID: 29236617 No abstract available.